Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Post-Mkt 08-31 16:21:58 EDT

60.22

+0.23

+0.38%

盘后60.22

+0.000.00%

16:15 EDT

High60.81	Low59.22	Vol751.97K
Open59.84	D1 Closing59.99	Amplitude2.65%
Mkt Cap5.82B	Tradable Cap5.75B	Total Shares96.64M
T/O45.12M	T/O Rate0.79%	Tradable Shares95.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":60.22,"timestamp":1788206400000,"preClose":59.99,"halted":0,"volume":751974,"hourTrading":{"tag":"盘后","latestPrice":60.22,"preClose":60.22,"latestTime":"16:15 EDT","volume":25995,"amount":1565415.2607,"timestamp":1788207300459,"change":0,"changeRate":0,"amplitude":0.000203},"delay":0,"changeRate":0.0038339723287214014,"floatShares":95449436,"shares":96642822,"eps":-4.706128,"marketStatus":"Post-Mkt","change":0.23,"latestTime":"08-31 16:21:58 EDT","open":59.84,"high":60.81,"low":59.22,"amount":45120216,"amplitude":0.026504,"askPrice":61.39,"askSize":32,"bidPrice":59.3,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-4.706128,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":59.99,"preHourTrading":{"tag":"盘前","latestPrice":60.04,"preClose":59.99,"latestTime":"09:26 EDT","volume":514,"amount":30950.927882,"timestamp":1788182807495,"change":0.05,"changeRate":0.000833,"amplitude":0.057676},"postHourTrading":{"tag":"盘后","latestPrice":60.22,"preClose":60.22,"latestTime":"16:15 EDT","volume":25995,"amount":1565415.2607,"timestamp":1788207300459,"change":0,"changeRate":0,"amplitude":0.000203},"volumeRatio":1.068834,"impliedVol":0.672,"impliedVolPercentile":0.7371},"requestUrl":"/m/hq/s/XENE/wiki","defaultTab":"wiki","newsList":[{"id":"2663013901","title":"Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013901?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947270,"startTime":"0","endTime":"0","summary":"Xenon grants 13,450 inducement stock options, 7,850 RSUs to new hires at $61.93 strikeXenon Pharmaceuticals granted inducement equity awards to five new non-officer employees, totaling 13,450 share op","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLbrG4sS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","BCDF","SBIO","IBRN","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4139","IE00BN0W2V16.EUR","BK4112","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","XENE","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013922","title":"Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013922?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nTUA9GT9VC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013769","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013769?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947260,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, Aug.  28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical devel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352881/33485/en/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SBIO","LCLG","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660520417","title":"Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660520417","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660520417?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:51","pubTimestamp":1787115071,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. recently reported second-quarter 2026 results, with net loss rising to US$110.74 million and basic loss per share from continuing operations at US$1.11, alongside a six‑month net loss of US$213.04 million and basic loss per share of US$2.28.\nThe widening losses compared with the same periods in 2025 give investors fresh insight into how Xenon is funding its ion-channel neurology pipeline ahead of key clinical and commercial milestones.\nWe will now examine how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-xenons-wider-q2-losses-to-fund-neurology-pipeline-req","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-xenons-wider-q2-losses-to-fund-neurology-pipeline-req","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IBRN","ISBC","BK4211","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659160360","title":"Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550","url":"https://stock-news.laohu8.com/highlight/detail?id=2659160360","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659160360?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:42","pubTimestamp":1786653738,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals director Steven Gannon disposes of 10,000 common shares for $640,550Xenon Pharmaceuticals director Steven Gannon sold 10,000 common shares on Aug. 11, 2026 at a weighted-average ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1zKHrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Xenon Pharmaceuticals Director Steven Gannon Disposes of 10,000 Common Shares for $640,550","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658343990","title":"J.P. Morgan Remains a Buy on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658343990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658343990?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:56","pubTimestamp":1786449382,"startTime":"0","endTime":"0","summary":"In a report released today, Tessa Romero from J.P. Morgan maintained a Buy rating on Xenon, with a price target of $82.00. Romero covers the Health...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-buy-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B3S45H60.SGD","LU2089283258.USD","LU0106261372.USD","LU0098860793.USD","LU2089284900.SGD","LU0106831901.USD","LU1732800096.USD","LU0053666078.USD","LU0882574139.USD","BK4534","LU1244550221.USD","LU0210528500.USD","SBIO","LU2028103732.USD","LU1074936037.SGD","LU1791710582.SGD","BK4588","LU1064131342.USD","LU0912757837.SGD","LU2133065610.SGD","LU0320765646.SGD","LU2264538146.SGD","XENE","LU1720051017.SGD","LU0225283273.USD","LU0795875169.SGD","LU0971096721.USD","LU2271345857.HKD","LU1720051108.HKD","LU0795875086.SGD","LU1244550494.USD","LU2357305700.SGD","KBWB","LU0158827781.USD","LU1363072403.SGD","LU2023251221.USD","BK4516","IBRN","LU0314104364.USD","BK4139","LU0390134368.USD","LU1791710400.SGD","LU1548497426.USD","LU1989772923.USD","LU1668664300.SGD","LU0234570918.USD","IE00B775SV38.USD","LU1244550577.SGD","LU1732799900.SGD","IAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658982377","title":"Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658982377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658982377?lang=en_us&edition=fundamental","pubTime":"2026-08-10 17:40","pubTimestamp":1786354831,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xenon-xene-relay-therapeutics-rlay-and-amylyx-pharmaceuticals-inc-amlx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xenon-xene-relay-therapeutics-rlay-and-amylyx-pharmaceuticals-inc-amlx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XBI","IBRN","HCSG","RLAY","BK4585","XLV","BK4581","XENE","BK4139","BK4137","BK4563","LU0128526141.USD","SBIO","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623471","title":"Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623471?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:00","pubTimestamp":1786129228,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oculis Holding (OCS) and Xenon (XENE) with bullish s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-oculis-holding-ocs-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","XENE","BK4007","OCS","SBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628087","title":"Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628087","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628087?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:02","pubTimestamp":1786125732,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals'  recent pre-NDA meeting with the FDA for azetukalner appeared constructive, supporting the drug's planned Q3 new drug application filing and potential 2027 launch, RBC Capital Markets said.The investment firm said in a Thursday note that azetukalner, Xenon's investigational treatment for focal onset seizures, remains on track for submission later this quarter. It added that the FDA appeared receptive to including all four doses on the drug's label.RBC said payer engagement has been encouraging, with potential for azetukalner to command a premium to Xcopri pricing given its novel mechanism of action, efficacy profile, lack of titration requirements, minimal drug-drug interactions and favorable tolerability.The investment firm also cited early-stage pain program data showing plasma and cerebrospinal fluid concentrations above predicted therapeutic exposures for Xenon's investigational candidates, though it said the safety profile remains unclear pending completion ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","SBIO","BK4585","BK4139","IBRN","XENE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657628527","title":"Evercore ISI Reaffirms Their Buy Rating on Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657628527","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657628527?lang=en_us&edition=fundamental","pubTime":"2026-08-08 01:15","pubTimestamp":1786122948,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Xenon today and set a price target of $80.00. Kasimov covers the Healthcare sector, fo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641325","title":"Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641325","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641325?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:42","pubTimestamp":1786110174,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of buy and mean price target of $80.74, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657491056","title":"RBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657491056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657491056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:27","pubTimestamp":1786109232,"startTime":"0","endTime":"0","summary":"RBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657080663","title":"Xenon Pharmaceuticals Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657080663","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657080663?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:01","pubTimestamp":1786050101,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30 - Earnings SummaryXenon Pharmaceuticals Inc.XENE.OQreported a quarterly adjusted loss of $1.11 per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665692","title":"Earnings Flash (XENE) Xenon Posts Q2 Loss Per Share $1.11, vs. FactSet Est of $1.14 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665692","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665692?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:00","pubTimestamp":1786050011,"startTime":"0","endTime":"0","summary":"Earnings Flash (XENE) Xenon Posts Q2 Loss Per Share $1.11, vs. FactSet Est of $1.14 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657765026","title":"Xenon Pharmaceuticals reports Q2 EPS ($1.11), consensus ($1.16)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657765026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657765026?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:18","pubTimestamp":1786047499,"startTime":"0","endTime":"0","summary":"“The second quarter of 2026 was marked by strong execution, including a successful pre-NDA meeting, and the NDA submission for azetukalner remains ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-reports-q2-eps-1-11-consensus-1-16-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-reports-q2-eps-1-11-consensus-1-16-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2324357040.USD","IBRN","NBIX","IE00B4R5TH58.HKD","PRAX","LU2065170008.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","PSIL","LU2065171402.SGD","LU0154245673.USD","SBIO","IE00BJT1NW94.SGD","BK4139","BK4563","LU0889565916.HKD","LU0823416689.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0154245756.USD","XENE","GHRS","IMRX","LU2065169927.USD","BK4539","IE0009355771.USD","BK4007","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571056","title":"Xenon Net Loss Widens 30.7% to $110.74 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571056?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:07","pubTimestamp":1786046831,"startTime":"0","endTime":"0","summary":"Xenon net loss widens 30.7% to $110.74 million in Q2 FY26Xenon posted a Q2 net loss of USD 110.7 million, widening from USD 84.7 million a year earlier.R&D costs rose to USD 99.2 million from USD 75 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbgCR29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IBRN","LU2210149790.SGD","IE00BKPKM429.USD","SBIO","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BCDF","IE00B3QW5Z07.USD","XENE","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657571","title":"Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657571","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657571?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046527,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.15) by 2.63 percent. This is a 3.74 percent decrease over losses of $(1.07) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61016422/xenon-pharmaceuticals-q2-eps-1-11-beats-1-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657365271","title":"Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657365271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657365271?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046521,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q2 Net Income USD -110.736 Million Vs. IBES Estimate USD -105.7 MillionAug 06 (Reuters) - Xenon Pharmaceuticals Q2 income from operations USD -123.155 million.Q2 operating expenses USD 123.155 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SBIO","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652480","title":"Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652480?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com;investor.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0493},{"period":"3month","weight":0.0961},{"period":"6month","weight":0.3877},{"period":"1year","weight":0.5541},{"period":"ytd","weight":0.3385}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.008322},{"month":2,"riseRate":0.75,"avgChangeRate":0.076063},{"month":3,"riseRate":0.25,"avgChangeRate":-0.040327},{"month":4,"riseRate":0.5,"avgChangeRate":0.017963},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.036246},{"month":6,"riseRate":0.5,"avgChangeRate":0.038173},{"month":7,"riseRate":0.416667,"avgChangeRate":0.020725},{"month":8,"riseRate":0.666667,"avgChangeRate":0.065223},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.05886},{"month":10,"riseRate":0.454545,"avgChangeRate":0.054946},{"month":11,"riseRate":0.727273,"avgChangeRate":0.050412},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089745}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}